SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced Wednesday preliminary safety and efficacy data from three clinical-stage programs targeting RAS-pathway malignancies. The ...

BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at ...

BEIJING, Dec 30 (Reuters) - China on Tuesday named the companies that will be able to export tungsten, antimony and silver during the 2026 and 2027 period, metals Beijing deems as critical to support ...

China's new cross-border data transfer regulations: What you need to know and do What to know about China’s new cross-border data transfer security assessment guidelines Notes from the IAPP Canada: ...